Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Cost of Revenue: 2020-2024

Historic Cost of Revenue for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $36.8 million.

  • Xeris Biopharma Holdings' Cost of Revenue fell 19.11% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year increase of 17.68%. This contributed to the annual value of $36.8 million for FY2024, which is 28.58% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Cost of Revenue stood at $36.8 million for FY2024, which was up 28.58% from $28.6 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Cost of Revenue peaked at $36.8 million during FY2024, and registered a low of $9.3 million during FY2020.
  • Over the past 3 years, Xeris Biopharma Holdings' median Cost of Revenue value was $28.6 million (recorded in 2023), while the average stood at $29.4 million.
  • Data for Xeris Biopharma Holdings' Cost of Revenue shows a peak YoY skyrocketed of 69.95% (in 2022) over the last 5 years.
  • Xeris Biopharma Holdings' Cost of Revenue (Yearly) stood at $9.3 million in 2020, then surged by 42.77% to $13.3 million in 2021, then skyrocketed by 69.95% to $22.6 million in 2022, then increased by 26.56% to $28.6 million in 2023, then climbed by 28.58% to $36.8 million in 2024.